Highest-materiality recent filing
Holders of all 49,263 Series A Preferred shares (100% outstanding) submitted redemption notices on June 29-30, 2026.
Lifecore stockholders approve 2026 equity plan; all director nominees elected at annual meeting
Stockholders approved 2026 Stock Incentive Plan (2.5M new shares plus forfeited 2019 Plan shares) effective Oct 16, 2026.
Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance
Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M
Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
Board changed fiscal year from May-ending to calendar year, effective May 26, 2025 – Dec 31, 2025.
Lifecore Biomedical adopts Incentive Bonus Plan for executives and key employees
Plan effective Jan 14, 2026; covers executive officers and selected employees.
Lifecore changes fiscal year to calendar year, effective May 26, 2025
Board approved fiscal year change on Aug 1, 2025; new calendar year ends Dec 31.
Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M
Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
Lifecore Biomedical stockholders elect nine directors and ratify KPMG at 2025 annual meeting
Katrina L. Houde, Humberto C. Antunes, Paul H. Johnson, Paul Josephs, Matthew E. Korenberg, Nelson Obus, Joshua E. Schechter elected by common and Series A holders.
Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary
New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.
Lifecore Biomedical dismisses BDO and appoints KPMG as new independent auditor
Audit Committee approved appointment of KPMG on August 12, 2025 as independent registered public accounting firm for transition period ending December 31, 2025.
Filing furnishes a presentation dated August 12, 2025 for investor discussions.
Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M
Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets
Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).
Lifecore Biomedical increases Equity Inducement Plan by 750,000 shares to 4,250,000 total
Board of Directors amended the Equity Inducement Plan on April 11, 2025, adding 750,000 shares.
Lifecore Biomedical shareholders approve issuance of shares beyond 19.99% threshold
At April 10, 2025 special meeting, stockholders approved the Issuance Proposal, allowing issuance of common stock underlying Series A Preferred Stock in excess of 19.99% of outstanding common shares.
Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M
Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.
Lifecore to hold special meeting April 10 to remove Series A preferred conversion cap
Special meeting on April 10, 2025 to vote on removing the 19.99% conversion cap on Series A Convertible Preferred Stock.
Lifecore sells excess 10-head isolator filler for $17M; strengthens financial position
Sale agreement for 10-head isolator filler with non-competitive buyer; purchase price $17M.
Lifecore Q2 FY25 revenue up 8% to $32.6M; net loss $6.6M on non-cash items; adj EBITDA $6.5M
Revenue $32.6M (+8% YoY); CDMO segment drove $1.9M increase, partially offset by customer mix shifts.
Lifecore extends BMO revolving credit facility to Nov 2027, lowers rates
Maturity extended three years to November 2027 under BMO ABL facility.
Lifecore Biomedical hosts Investor Day; presentation signals new strategic era
Lifecore Biomedical hosted an Investor Day on November 21, 2024, releasing a presentation.
Lifecore Biomedical annual meeting elects five directors, ratifies auditor, approves say-on-pay
Matthew Korenberg, Humberto Antunes, Nelson Obus, Katrina Houde elected by common and preferred holders voting together; Christopher Kiper elected solely by preferred holders.
Lifecore raises $24.3M via stock sale; Q1 net loss widens to $16.2M, reaffirms FY25 guidance
Sold 5,928,775 shares at $4.10 for gross proceeds of $24.3M to investors including Legion Partners, Greenhaven, Wynnefield, 325 Capital.
Lifecore Biomedical announces two director departures, Nov 7 annual meeting
Jeffrey L. Edwards will not stand for re-election; Ray Diradoorian resigns effective before 2024 annual meeting.
Lifecore Biomedical regains Nasdaq compliance, avoids delisting
Filed overdue Q3 FY2023 and Q1/Q2 FY2024 10-Qs on Aug 8, 2024, and FY2024 10-K on Aug 26, 2024.
Lifecore appoints Ryan Lake as CFO effective Sept 3; Morberg departs Sept 2
John Morberg steps down as CFO effective Sept 2, 2024; Ryan Lake succeeds him on Sept 3, 2024.
Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M
FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).
Lifecore shareholders approve board declassification, share increase; appoints four new directors
Shareholders approved phased-in board declassification: 21.6M for, 77K against.
Lifecore Biomedical approves FY2025 Annual Incentive Plan with EBITDA-based bonuses
CEO Paul Josephs target bonus 100% of base salary; CFO John D. Morberg 60%.
Lifecore Biomedical cuts 46 jobs (9% of workforce); expects $1.0M in severance costs
Workforce Reduction Plan eliminates 46 full-time employees, approximately 9% of total workforce.
Lifecore settles proxy fight with 22NW, adds four new directors and declassification proposal
22NW withdraws director nominations and special meeting demand; board declassification proposal at 2023 annual meeting.
Lifecore receives Nasdaq delisting notice for missing annual meeting and filing delays
Nasdaq notified Lifecore on June 3, 2024 of non-compliance with listing rules.
Lifecore CEO James Hall resigns; Paul Josephs appointed CEO and director effective May 20
James G. Hall resigned as director, President and CEO effective May 19, 2024.
Lifecore adds ~$8M non-dilutive liquidity via lender amendments; assigns Curation Foods assets
$5.5M prepayment from term lender as advance on future purchases; lender can apply to invoices in 2026.
Lifecore amends ABL facility with FILO tranche; still faces Nasdaq delisting risk
Entered FILO tranche under ABL credit agreement with BMO; FILO loans bear SOFR +4.25%.
Lifecore gets $5.5M prepayment from Alcon; annual meeting set for Aug 15, 2024
Alcon Research paid $5.5M prepayment for future product purchases; credits apply in 2026.
Lifecore changes executive incentive from cash to stock for FY2024
CFO John D. Morberg and James G. Hall will receive FY2024 incentive in fully vested, unrestricted shares instead of cash.
Lifecore Biomedical appoints BDO USA as independent auditor for FY 2024
Audit committee approved BDO USA as independent auditor effective April 29, 2024 for fiscal year ending May 26, 2024.
Lifecore receives Nasdaq notice for delayed Q3 10-Q; hearing held April 16, decision pending
Nasdaq notice on April 15, 2024, cites continued non-compliance with Listing Rule 5250(c)(1) due to late Q3 10-Q and prior Q1/Q2 filings.
Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)
Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.
EY declines reappointment as Lifecore auditor; cites material weaknesses in internal controls
Ernst & Young notified Lifecore on March 20, 2024 it will not stand for reappointment as auditor for FY ending May 26, 2024.
Lifecore appoints Paul Josephs as CEO; concludes strategic review, remains standalone
Paul Josephs becomes President & CEO effective May 20, 2024, succeeding James Hall, who retires after 30+ years.
Lifecore files FY23 10-K with restatements for FY21-22; corrects inventory and interest errors
Filed FY23 Annual Report on Form 10-K with SEC on March 20, 2024, restating FY22, FY21, and multiple quarterly periods.
Lifecore receives Nasdaq delisting notice for failure to file FY 2023 10-K and Q1/Q2 10-Qs
Nasdaq initiated delisting process on Feb 13, 2024 due to non-compliance with Listing Rule 5250(c)(1).
Lifecore Biomedical receives Nasdaq notice for delayed quarterly and annual filings
Nasdaq notified Lifecore on Jan 10, 2024 that it is not compliant with Listing Rule 5250(c)(1) due to delayed Q2 Form 10-Q and continued delays in Form 10-K and Q1 Form 10-Q.
Lifecore expands Alcon CDMO contract through 2031; receives credit waivers on delayed reports
Entered 8-year Amended CMA with Alcon through Dec 2031 for aseptic manufacturing of ophthalmic devices.
DOJ declines prosecution of Lifecore for FCPA violations; $406,505 disgorgement agreed
DOJ declines to prosecute Lifecore for FCPA violations involving former subsidiary Yucatan Foods.
Audit committee concludes prior financials for FY21, FY22, and interim periods 2020-2023 should no longer be relied upon.
Lifecore receives Nasdaq delisting notice for delayed filings; compliance plan submitted
Received Nasdaq notice on Oct 12, 2023 for failure to timely file Form 10-Q (period ended Aug 27, 2023) and still-delinquent Form 10-K (period ended May 28, 2023).
Jeffrey L. Edwards notified Lifecore Biomedical, Inc. (the “Company”) that he has elected not to stand for re-election to serve as a director of the Board of Directors of the Company (the “Board”) at the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”)
Ray Diradoorian notified the Company that he intends to resign as a director of the Board effective as of immediately prior to the Annual Meeting.
On August 28, 2024, the Company appointed Ryan D. Lake as the Company’s Chief Financial Officer and Secretary, effective September 3, 2024
Mr. Morberg's separation will be treated as a termination by the Company without Cause subsequent to a Change in Control under that certain Executive Employment Agreement (the "Morberg Employment Agreement"), dated January 19, 2021, between the Company and Mr. Morberg
the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors
the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors
the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors
the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
Effective May 19, 2024, James G. Hall resigned as a director of the Company and ceased serving as the Company’s President and Chief Executive Officer.
Max materiality 0.85 · Median 0.65 · Most common event other_material